肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2012 ESMO临床实践指南：鼻咽癌的诊断、治疗与随访

2012-06-01 欧洲肿瘤内科学会 Annals of Oncology 23 (Supplement 7): vii83–vii85, 2012 发表于上海

ESMO鼻咽癌

中文标题：

2012 ESMO临床实践指南：鼻咽癌的诊断、治疗与随访

英文标题：

Nasopharyngeal cancer: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

发布机构：

欧洲肿瘤内科学会

发布日期：

2012-06-01

简要介绍：

《2012 ESMO临床实践指南：鼻咽癌的诊断、治疗与随访》更新了2010年的版本！

相关资料下载：
[AttachmentFileName(sort=100, fileName=2012 ESMO临床实践指南：鼻咽癌的诊断、治疗与随访)] GetToolGuiderByIdResponse(projectId=1, id=a4f671c0009133d0, title=2012 ESMO临床实践指南：鼻咽癌的诊断、治疗与随访, enTitle=Nasopharyngeal cancer: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up†, guiderFrom=Annals of Oncology 23 (Supplement 7): vii83–vii85, 2012, authorId=null, author=, summary=, cover=, journalId=null, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会（ESMO，European Society for Medical Oncology )是1975年成立的非盈利组织，是欧洲领先的专业组织，致力于提高肿瘤内科的专业性，推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Fri Jun 01 08:00:00 CST 2012, originalUrl=http://guide.medlive.cn/guideline/4810, linkOutUrl=, content=《2012 ESMO临床实践指南：鼻咽癌的诊断、治疗与随访》更新了2010年的版本！, tagList=[TagDto(tagId=468, tagName=ESMO), TagDto(tagId=1574, tagName=鼻咽癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=30, categoryName=耳鼻咽喉科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100), CategoryDto(categoryId=21120, categoryName=PICOST思维引领下的鼻咽癌免疫治疗临床研究设计, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=null, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3667, appHits=373, showAppHits=13, pcHits=2114, showPcHits=1506, likes=146, shares=5, comments=9, approvalStatus=1, publishedTime=Fri Jun 01 00:00:00 CST 2012, publishedTimeString=2012-06-01, pcVisible=1, appVisible=1, editorId=null, editor=null, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=null, createdTime=Fri Jun 01 00:00:00 CST 2012, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Thu Jun 27 09:55:14 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2012 ESMO临床实践指南：鼻咽癌的诊断、治疗与随访)])
2012 ESMO临床实践指南：鼻咽癌的诊断、治疗与随访
下载请点击：
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2089790, encodeId=55e12089e9006, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3286305161, createdName=3577330_8241, createdTime=Thu Sep 22 16:07:54 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206220, encodeId=5ef21206220e8, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c04867686, createdName=188447f5f4m, createdTime=Sat Mar 26 21:30:11 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976118, encodeId=3ff29e611805, content=梅斯医学很赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Wed Jun 23 10:36:47 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956221, encodeId=2dd695622187, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3885479690, createdName=anjing1127, createdTime=Mon Apr 12 17:33:56 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956220, encodeId=fa5d9562207f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3885479690, createdName=anjing1127, createdTime=Mon Apr 12 17:33:47 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2022-09-22 3577330_8241

    谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2089790, encodeId=55e12089e9006, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3286305161, createdName=3577330_8241, createdTime=Thu Sep 22 16:07:54 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206220, encodeId=5ef21206220e8, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c04867686, createdName=188447f5f4m, createdTime=Sat Mar 26 21:30:11 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976118, encodeId=3ff29e611805, content=梅斯医学很赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Wed Jun 23 10:36:47 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956221, encodeId=2dd695622187, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3885479690, createdName=anjing1127, createdTime=Mon Apr 12 17:33:56 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956220, encodeId=fa5d9562207f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3885479690, createdName=anjing1127, createdTime=Mon Apr 12 17:33:47 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2022-03-26 188447f5f4m

    学习！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2089790, encodeId=55e12089e9006, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3286305161, createdName=3577330_8241, createdTime=Thu Sep 22 16:07:54 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206220, encodeId=5ef21206220e8, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c04867686, createdName=188447f5f4m, createdTime=Sat Mar 26 21:30:11 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976118, encodeId=3ff29e611805, content=梅斯医学很赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Wed Jun 23 10:36:47 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956221, encodeId=2dd695622187, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3885479690, createdName=anjing1127, createdTime=Mon Apr 12 17:33:56 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956220, encodeId=fa5d9562207f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3885479690, createdName=anjing1127, createdTime=Mon Apr 12 17:33:47 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2021-06-23 湘雅科教

    梅斯医学很赞

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2089790, encodeId=55e12089e9006, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3286305161, createdName=3577330_8241, createdTime=Thu Sep 22 16:07:54 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206220, encodeId=5ef21206220e8, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c04867686, createdName=188447f5f4m, createdTime=Sat Mar 26 21:30:11 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976118, encodeId=3ff29e611805, content=梅斯医学很赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Wed Jun 23 10:36:47 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956221, encodeId=2dd695622187, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3885479690, createdName=anjing1127, createdTime=Mon Apr 12 17:33:56 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956220, encodeId=fa5d9562207f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3885479690, createdName=anjing1127, createdTime=Mon Apr 12 17:33:47 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2021-04-12 anjing1127

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2089790, encodeId=55e12089e9006, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3286305161, createdName=3577330_8241, createdTime=Thu Sep 22 16:07:54 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206220, encodeId=5ef21206220e8, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c04867686, createdName=188447f5f4m, createdTime=Sat Mar 26 21:30:11 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976118, encodeId=3ff29e611805, content=梅斯医学很赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Wed Jun 23 10:36:47 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956221, encodeId=2dd695622187, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3885479690, createdName=anjing1127, createdTime=Mon Apr 12 17:33:56 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956220, encodeId=fa5d9562207f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3885479690, createdName=anjing1127, createdTime=Mon Apr 12 17:33:47 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2021-04-12 anjing1127

    感谢分享

    0

相关指南

2012 ESMO临床实践指南：非上皮性卵巢癌的诊治与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2012 ESMO临床实践指南：肝细胞癌的诊治与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2012 ESMO临床实践指南：骨肉瘤的诊治与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2012 ESMO临床实践指南：软组织和内脏肉瘤的诊治与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2012 ESMO临床实践指南：肾细胞癌的诊治及随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2012 ESMO临床实践指南：胰腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01